EGFR 突变晚期 NSCLC 新突破：Izalontamab Brengitecan 优于含铂化疗
Posted inClinical Updates Oncology Respiratory

Izalontamab Brengitecan Shows Promising Efficacy Over Platinum Chemotherapy in EGFR-Mutated NSCLC Post-Third-Generation EGFR TKI Progression

The PANKU-Lung01 phase 3 trial demonstrates izalontamab brengitecan significantly extends progression-free survival compared to platinum-based chemotherapy in EGFR-mutated advanced non-squamous NSCLC after failure of third-generation EGFR TKIs, with manageable safety profile.
Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma
Posted innews Oncology

Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma

A phase 3 randomized trial in China showed the EGFR/HER3 bispecific antibody‑drug conjugate izalontamab brengitecan produced a 54.6% objective response rate versus 27.0% with chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, though hematologic toxicity was substantial.